CoChat
Sign Up
Cited by 207Mosquito-borne diseases and controlViral Infections and VectorsDengue and Mosquito Control Research

Cross-serotype interactions and disease outcome prediction of dengue infections in Vietnam

Open access
Aguas, R., Dorigatti, I., Coudeville, L., Luxemburger, C., Ferguson, N. M.·2019·Scientific Reports
DOI 10.1038/s41598-019-45816-6PMC PMC6598999
Open this paper in CoChat — free accountOpen PDF

Abstract

Dengue pathogenesis is extremely complex. Dengue infections are thought to induce life-long immunity from homologous challenges as well as a multi-factorial heterologous risk enhancement. Here, we use the data collected from a prospective cohort study of dengue infections in schoolchildren in Vietnam to disentangle how serotype interactions modulate clinical disease risk in the year following serum collection. We use multinomial logistic regression to correlate the yearly neutralizing antibody measurements obtained with each infecting serotype in all dengue clinical cases collected over the course of 6 years (2004–2009). This allowed us to extrapolate a fully discretised matrix of serotype interactions, revealing clear signals of increased risk of clinical illness in individuals primed with a previous dengue infection. The sequences of infections which produced a higher risk of dengue fever upon secondary infection are: DEN1 followed by DEN2; DEN1 followed by DEN4; DEN2 followed by DEN3; and DEN4 followed by DEN3. We also used this longitudinal data to train a machine learning algorithm on antibody titre differences between consecutive years to unveil asymptomatic dengue infections and estimate asymptomatic infection to clinical case ratios over time, allowing for a better characterisation of the population’s past exposure to different serotypes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-019-45816-6

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Host immunity factors, such as serotype interaction, antibody-dependent enhancement and cross-immunity, complicate the clinical course of dengue, leading to challenges in managing severe cases.

    “Host immunity factors, such as serotype interaction, antibody-dependent enhancement and cross-immunity, complicate the clinical course, which leads to challenges in managing severe cases. (1, 7)”

    From Epidemiology of dengue reported in the World Health Organization Western Pacific Region, 2013–2019 (2023) · cites this paper as [7]

    The Introduction and Discussion (page numbers unavailable) describe cross-serotype immunity, antibody-dependent enhancement, and serotype-specific interactions that affect dengue illness risk. The Discussion says routine serological screening in large populations is challenging, but it does not establish that these immune factors cause challenges in managing severe cases specifically. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 59

  1. [1]Brady OJ Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus PLoS Negl. Trop. Dis. 2012 6 e1760 10.1371/journal.pntd.0001760 22880140 PMC3413714 · DOI
  2. [3]Salje H Reconstruction of antibody dynamics and infection histories to evaluate dengue risk Nature 2018 557 719 723 10.1038/s41586-018-0157-4 29795354 PMC6064976 · DOI
  3. [4]Recker M Immunological serotype interactions and their effect on the epidemiological pattern of dengue Proc. R. Soc. B Biol. Sci. 2009 276 2541 2548 10.1098/rspb.2009.0331 PMC2684681 19369266 · DOI
  4. [5]Nisalak A Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999 Am. J. Trop. Med. Hyg. 2003 68 191 202 10.4269/ajtmh.2003.68.191 12641411 · DOI
  5. [6]Wearing HJ Rohani P Ecological and immunological determinants of dengue epidemics Proc. Natl. Acad. Sci. 2006 103 11802 11807 10.1073/pnas.0602960103 16868086 PMC1544250 · DOI
  6. [7]Adams B Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok Proc. Natl. Acad. Sci. 2006 103 14234 14239 10.1073/pnas.0602768103 16966609 PMC1599940 · DOI
  7. [8]Adams B Boots M Modelling the relationship between antibody-dependent enhancement and immunological distance with application to dengue J. Theor. Biol. 2006 242 337 346 10.1016/j.jtbi.2006.03.002 16631802 · DOI
  8. [9]Ferguson NM Donnelly CA Anderson RM Transmission dynamics and epidemiology of dengue: insights from age-stratified sero-prevalence surveys Philos. Trans. R. Soc. B Biol. Sci. 1999 354 757 768 10.1098/rstb.1999.0428 PMC1692557 10365401 · DOI
  9. [10]Stephens HAF HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais Tissue Antigens 2002 60 309 18 10.1034/j.1399-0039.2002.600405.x 12472660 · DOI
  10. [11]Sakuntabhai A A variant in the CD209 promoter is associated with severity of dengue disease Nat. Genet. 2005 37 507 513 10.1038/ng1550 15838506 PMC7096904 · DOI
  11. [12]Nguyen TH Association between sex, nutritional status, severity of dengue hemorrhagic fever, and immune status in infants with dengue hemorrhagic fever Am. J. Trop. Med. Hyg. 2005 72 370 4 10.4269/ajtmh.2005.72.370 15827272 · DOI
  12. [13]Rico-Hesse R Molecular evolution of dengue type 2 virus in Thailand Am. J. Trop. Med. Hyg. 1998 58 96 101 10.4269/ajtmh.1998.58.96 9452299 · DOI
  13. [14]Leitmeyer KC Dengue virus structural differences that correlate with pathogenesis J. Virol. 1999 73 4738 47 10233934 PMC112516
  14. [16]Balmaseda A Serotype-specific differences in clinical manifestations of dengue Am. J. Trop. Med. Hyg. 2006 74 449 56 10.4269/ajtmh.2006.74.449 16525106 · DOI
  15. [17]OhAinle M Dynamics of Dengue Disease Severity Determined by the Interplay Between Viral Genetics and Serotype-Specific Immunity Sci. Transl. Med. 2011 3 114ra128 114ra128 10.1126/scitranslmed.3003084 PMC4517192 22190239 · DOI
  16. [18]Alvarez M Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002 Am. J. Trop. Med. Hyg. 2006 75 1113 7 10.4269/ajtmh.2006.75.1113 17172378 · DOI
  17. [19]SABIN AB Research on dengue during World War II Am. J. Trop. Med. Hyg. 1952 1 30 50 10.4269/ajtmh.1952.1.30 14903434 · DOI
  18. [20]Halstead SB Neutralization and antibody-dependent enhancement of dengue viruses Adv. Virus Res. 2003 60 421 67 10.1016/S0065-3527(03)60011-4 14689700 · DOI
  19. [21]Guzmán MG Effect of age on outcome of secondary dengue 2 infections Int. J. Infect. Dis. 2002 6 118 24 10.1016/S1201-9712(02)90072-X 12121599 · DOI
  20. [22]Burke DS Nisalak A Johnson DE Scott RM A prospective study of dengue infections in Bangkok Am. J. Trop. Med. Hyg. 1988 38 172 80 10.4269/ajtmh.1988.38.172 3341519 · DOI
  21. [23]Kochel TJ Cross‐Serotype Neutralization of Dengue Virus in Aotus nancymae Monkeys J. Infect. Dis. 2005 191 1000 1004 10.1086/427511 15717278 · DOI
  22. [24]Boonnak K Role of Dendritic Cells in Antibody-Dependent Enhancement of Dengue Virus Infection J. Virol. 2008 82 3939 3951 10.1128/JVI.02484-07 18272578 PMC2292981 · DOI
  23. [25]Halstead SB O’Rourke EJ Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody J. Exp. Med. 1977 146 201 17 10.1084/jem.146.1.201 406347 PMC2180729 · DOI
  24. [26]Rothman AL Dengue: defining protective versus pathologic immunity J. Clin. Invest. 2004 113 946 951 10.1172/JCI21512 15057297 PMC379334 · DOI
  25. [27]Rothman AL Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms Nat. Rev. Immunol. 2011 11 532 543 10.1038/nri3014 21760609 · DOI
  26. [28]Gibbons RV Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences Am. J. Trop. Med. Hyg. 2007 77 910 3 10.4269/ajtmh.2007.77.910 17984352 · DOI
  27. [29]Waggoner JJ Homotypic Dengue Virus Reinfections in Nicaraguan Children J. Infect. Dis. 2016 214 986 993 10.1093/infdis/jiw099 26984144 PMC5021223 · DOI
  28. [30]Forshey Brett M. Reiner Robert C. Olkowski Sandra Morrison Amy C. Espinoza Angelica Long Kanya C. Vilcarromero Stalin Casanova Wilma Wearing Helen J. Halsey Eric S. Kochel Tadeusz J. Scott Thomas W. Stoddard Steven T. Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru PLOS Neglected Tropical Diseases 2016 10 2 e0004398 10.1371/journal.pntd.0004398 26848841 PMC4746126 · DOI
  29. [31]Cummings DAT The Impact of the Demographic Transition on Dengue in Thailand: Insights from a Statistical Analysis and Mathematical Modeling PLoS Med. 2009 6 e1000139 10.1371/journal.pmed.1000139 19721696 PMC2726436 · DOI
  30. [32]Sangkawibha N Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak Am. J. Epidemiol. 1984 120 653 69 10.1093/oxfordjournals.aje.a113932 6496446 · DOI
  31. [33]Halstead SB Nimmannitya S Cohen SN Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered Yale J. Biol. Med. 1970 42 311 28 5419206 PMC2591704
  32. [34]Nagao Y Koelle K Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever Proc. Natl. Acad. Sci. 2008 105 2238 2243 10.1073/pnas.0709029105 18250338 PMC2538904 · DOI
  33. [35]Libraty DH A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model PLoS Med. 2009 6 e1000171 10.1371/journal.pmed.1000171 19859541 PMC2762316 · DOI
  34. [36]Graham RR A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996 Am. J. Trop. Med. Hyg. 1999 61 412 9 10.4269/ajtmh.1999.61.412 10497982 · DOI
  35. [37]Endy TP Relationship of Preexisting Dengue Virus (DV) Neutralizing Antibody Levels to Viremia and Severity of Disease in a Prospective Cohort Study of DV Infection in Thailand J. Infect. Dis. 2004 189 990 1000 10.1086/382280 14999601 · DOI
  36. [38]Katzelnick LC Antibody-dependent enhancement of severe dengue disease in humans Science (80-.). 2017 358 929 932 10.1126/science.aan6836 PMC5858873 29097492 · DOI
  37. [39]Changal, K. H. et al. Differentiating secondary from primary dengue using IgG to IgM ratio in early dengue: an observational hospital based clinico-serological study from North India, 10.1186/s12879-016-2053-6. PMC5127094 27894268 · DOI
  38. [40]Hanh Tien Nguyen, T. et al. Methods to discriminate primary from secondary dengue during acute symptomatic infection, 10.1186/s12879-018-3274-7. PMC6081805 30086716 · DOI
  39. [41]Jayathilaka, D. et al. Role of NS1 antibodies in the pathogenesis of acute secondary dengue infection, 10.1038/s41467-018-07667-z. PMC6286345 30531923 · DOI
  40. [42]Tien NTK A prospective cohort study of dengue infection in schoolchildren in Long Xuyen, Viet Nam Trans. R. Soc. Trop. Med. Hyg. 2010 104 592 600 10.1016/j.trstmh.2010.06.003 20630553 · DOI
  41. [43]Khurram M Dengue hemorrhagic fever: Comparison of patients with primary and secondary infections J. Infect. Public Health 2014 7 489 495 10.1016/j.jiph.2014.05.005 24999118 · DOI
  42. [45]Davidson, R. & MacKinnon, J. G. Econometric theory and methods. (Oxford University Press, 2009).
  43. [46]Dorigatti I Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning Nat. Commun. 2018 9 3644 10.1038/s41467-018-06006-6 30194294 PMC6128884 · DOI
  44. [47]Breiman L Random Forests Mach. Learn. 2001 45 5 32 10.1023/A:1010933404324 · DOI · Paper page
  45. [48]Saeys Y Inza I Larranaga P A review of feature selection techniques in bioinformatics Bioinformatics 2007 23 2507 2517 10.1093/bioinformatics/btm344 17720704 · DOI
  46. [49]Lai C-Y Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II J. Virol. 2008 82 6631 43 10.1128/JVI.00316-08 18448542 PMC2447043 · DOI
  47. [50]Buddhari D Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies PLoS Negl. Trop. Dis. 2014 8 e3230 10.1371/journal.pntd.0003230 25329173 PMC4199527 · DOI
  48. [51]Morens DM Halstead SB Marchette NJ Profiles of antibody-dependent enhancement of dengue virus type 2 infection Microb. Pathog. 1987 3 231 237 10.1016/0882-4010(87)90056-8 3504546 · DOI
  49. [52]Pierson TC The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection Cell Host Microbe 2007 1 135 45 10.1016/j.chom.2007.03.002 18005691 PMC2656919 · DOI
  50. [53]Dowd KA Pierson TC Antibody-mediated neutralization of flaviviruses: a reductionist view Virology 2011 411 306 15 10.1016/j.virol.2010.12.020 21255816 PMC3100196 · DOI
  51. [54]van Panhuis WG Inferring the Serotype Associated with Dengue Virus Infections on the Basis of Pre‐ and Postinfection Neutralizing Antibody Titers J. Infect. Dis. 2010 202 1002 1010 10.1086/656141 20738205 PMC2943243 · DOI
  52. [55]Endy TP Determinants of Inapparent and Symptomatic Dengue Infection in a Prospective Study of Primary School Children in Kamphaeng Phet, Thailand PLoS Negl. Trop. Dis. 2011 5 e975 10.1371/journal.pntd.0000975 21390158 PMC3046956 · DOI
  53. [56]Endy TP Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand Am. J. Epidemiol. 2002 156 40 51 10.1093/aje/kwf005 12076887 · DOI
  54. [57]Guzman M. G. Epidemiologic Studies on Dengue in Santiago de Cuba, 1997 American Journal of Epidemiology 2000 152 9 793 799 10.1093/aje/152.9.793 11085389 · DOI
  55. [58]Weaver SC Vasilakis N Molecular evolution of dengue viruses: Contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease Infect. Genet. Evol. 2009 9 523 540 10.1016/j.meegid.2009.02.003 19460319 PMC3609037 · DOI
  56. [59]Zellweger RM Role of humoral versus cellular responses induced by a protective dengue vaccine candidate PLoS Pathog. 2013 9 e1003723 10.1371/journal.ppat.1003723 24204271 PMC3814346 · DOI
  57. [60]Balsitis SJ Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification PLoS Pathog. 2010 6 e1000790 10.1371/journal.ppat.1000790 20168989 PMC2820409 · DOI
  58. [61]Wang TT IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity Science (80-.). 2017 355 395 398 10.1126/science.aai8128 PMC5557095 28126818 · DOI
  59. [62]Luo S Seroprevalence of dengue IgG antibodies in symptomatic and asymptomatic individuals three years after an outbreak in Zhejiang Province, China BMC Infect. Dis. 2018 18 92 10.1186/s12879-018-3000-5 29471783 PMC5824482 · DOI

Cited by

Sorted by citations

Authors
Aguas, R., Dorigatti, I., Coudeville, L., Luxemburger, C., & Ferguson, N. M.
Affiliations
  • Mahidol University (TH)
  • Imperial College London (GB)
  • Sanofi (France) (FR)
Corresponding author
Aguas, R.
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2019-06-28
Volume
9
Issue
1
Pages
9395-9395
ISSN
2045-2322 (ISSN-L)
DOI
10.1038/s41598-019-45816-6
PMC
PMC6598999
OpenAlex
W2956118262
Cited by
207
References
2
Citations by year
2026: 3 · 2025: 12 · 2024: 6 · 2023: 159 · 2022: 5 · 2021: 13 · 2020: 8 · 2019: 1
FWCI
6.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • Bill and Melinda Gates Foundation
  • Imperial College London
  • Sanofi Pasteur
  • RCUK | Medical Research Council
  • U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Mosquito-borne diseases and control
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Vectors
  • Social Sciences › Sociology and Political Science › Dengue and Mosquito Control Research
Keywords
dengue, secondary dengue infection, neutralizing antibodies, disease outcome prediction, asymptomatic dengue infection, elementary school students, dengue epidemiology, Vietnam
MeSH terms
Algorithms, Antibodies, Viral, Cross Reactions, Dengue, Dengue Virus, Female, Humans, Male, Models, Theoretical, Population Surveillance, Vietnam, Odds Ratio, Antibodies, Neutralizing, Serogroup

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review